3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
10
Thoracic
8
Gastrointestinal
7
Tumor-Agnostic
3
Sarcoma
2
Head & Neck
2
Endocrine
2
Breast
2
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Genitourinary
1
Dermatologic
1
Conditions
Pheochromocytoma
1
Paraganglioma
1
Neuroendocrine Tumors
1
Interventions
Everolimus
10
lutetium Lu 177 dotatate
7
Magnetic Resonance Spectroscopy
7
pasireotide
4
Specimen Handling
3
Positron Emission Tomography Computed Tomography
3
Nivolumab
3
Ga(III)-DOTATOC
3
Fluorodeoxyglucose F18
3
(177)Lu-DOTA-EB-TATE
3
olaparib
2
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Lutetium-177
2
Ipilimumab
2
FAPI-46
2
veliparib
1
vandetanib
1
trifluridine tipiracil drug combination
1
toripalimab
1
tislelizumab
1
talazoparib
1
surufatinib
1
romidepsin
1
peposertib
1
pembrolizumab
1
pelcitoclax
1
pegfilgrastim
1
lanreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
vandetanib
×
NET
×
Clear all
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn